Items Tagged ‘zydelig’

November 18th, 2015

Zydelig® Combined with Treanda and Rituxan Appears Promising in Treatment of Chronic Lymphocytic Leukemia

By

Following the recommendation by an independent Data Monitoring Committee (DMC), Gilead Sciences, Inc today announced that its Phase 3 clinical study evaluating Zydelig® (idelalisib) added to standard therapy in previously-treated chronic lymphocytic leukemia (CLL) patients will be unblinded early. The DMC recommendation is based upon a predefined interim analysis indicating a benefit in patients receiving […]

View full entry

Tags: Chronic Lymphocytic Leukemia, CLL, News, Phase III clinical trial, rituxan, Treanda, zydelig


August 25th, 2014

FDA Approves New Treatment Options for Low Grade Lymphomas and Chronic Lymphocytic Leukemia

By

Gilead Sciences has confirmed FDA approval of Zydelig (idelalisib) for relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL). Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the cells of the lymph system. The lymph system includes the spleen, thymus, tonsils, bone marrow, lymph nodes, and circulating immune […]

View full entry

Tags: Chronic Lymphoblastic Leukemia, CLL, Leukemia, News, zydelig